Quantitative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma

Oncology

Volumn 65, Issue 2, 2003, Pages 125-131

  Morita, Tatsuo ^a   Matsuzaki, Atsushi ^a   Tokue, Akihiko ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Dihydropyrimidine dehydrogenase; Fluoropyrimidines; Prognosis; Renal cell carcinoma; Thymidine phosphorylase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; THYMIDINE PHOSPHORYLASE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER STAGING; CONTROLLED STUDY; DEATH; DIAGNOSTIC PROCEDURE; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

AGED; CARCINOMA, RENAL CELL; DIHYDROURACIL DEHYDROGENASE (NADP); ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXIDOREDUCTASES; PROGNOSIS; SURVIVAL ANALYSIS; THYMIDINE PHOSPHORYLASE; TUMOR MARKERS, BIOLOGICAL;

EID: 0042924392     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072337     Document Type: Article

References (40)

1. Belldegrun A, Abi-Aad AS, Figlin RA, DeKernion JB: Renal cell carcinoma: Basic biology and current approaches to therapy. Semin Urol 1991;18:96-101.
2. Hrouda D, Muir GH, Dalgleish AG: The role of immunotherapy for urological tumours. Br J Urol 1997;79:307-316.
3. Swanson DA: Is cytotoxic chemotherapy effective in the treatment of advanced renal cell carcinoma? Semin Urol 1993;11:35-40.
4. Sella A, Logothetics CJ, Fitz K, Dexeus FH, Amato R, Kilbourn R, Wallace S: Phase II study of interferon-α and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. J Urol 1992;147:573-577.
5. Atzpodien J, Kirchner H, Hanninen EL, Deckert M, Fenner M, Poliwoda H: Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell carcinoma. Eur J Cancer 1993;29:S6-S8.
6. Haarstad H, Jacobsen AB, Schjlseth SA, Risberg T, Fossa SD: Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma: A phase II study. Ann Oncol 1994;5:245-248.
7. Elias L, Blumenstein BA, Kish J, Flanigan RC, Wade JL, Lowe BA, Goodwin JW, Crawford ED: A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group Study. Cancer 1996;78:1085-1088.
8. Gebrosky NP, Koukol S, Nseyo UO, Carpenter C, Lamm DL: Treatment of renal cell carcinoma with 5-fluorouracil and alpha-interferon. Urology 1997;50:863-868.
9. Atzpodien J, Kirchner H, Illiger HJ, Metzner B, Ukena D, Schott H, Funke PJ, Gramatzki M, Jurgenson S, Wandert T, Patzelt T, Reitz M: IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: Long-term results of a controlled randomized clinical trial. Br J Cancer 2001;85: 1130-1136.
10. Rini BI, Vogelzang NJ, Dumas MC, Wade JL 3rd, Taber DA, Stadler WM: Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 2000;18: 2419-2426.
11. Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ: Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: A potential broadly active regimen for advanced solid tumor malignancies. Cancer 2001;92:1567-1576.
12. Heidelberger C, Chaudhuri NK, Danneberg P: Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 1957;179:663-666.
13. Cook AF, Holman MJ, Kramer MJ: Fluorinated pyrimidine nucleosides. 4. Synthesis and antitumor testing of a series of 2′,5′-dideoxy- and 2′,3′,5′-trideoxynucleosides of 5-fluorouracil. J Med Chem 1980;23:852-857.
14. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
15. Ishikawa T, Fukase Y, Yamamoto T, Sekiguchi F, Ishitsuka H: Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5′-deoxy-5-fluorocytidine (capecitabine). Biol Pharm Bull 1998;21:713-717.
16. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K, Ishizawa M, Yamada Y: Angiogenic factor. Nature 1992;356:668.
17. Haraguchi M, Miyadera K, Uemura K, Sumizawa T, Furukawa T, Yamada K, Akiyama S, Yamada Y: Angiogenic activity of enzymes. Nature 1994;368:198.
18. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W, Heldin CH: Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989;338:557-562.
19. Diasio RB: Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology (Huntingt) 2001;15:21-26.
20. Koizumi W, Saigenji K, Nakamaru N, Okayasu I, Kurihara M: Prediction of response to 5′-deoxy-5-fluorouridine (5′-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor. Oncology 1999;56:215-222.
21. Fox SB, Engels K, Comley M, Whitehouse RM, Turley H, Gatter KC, Harris AL: Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann Oncol 1997;8: 271-275.
22. Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E, Morabito A, Fanelli M, Gatti C, Suzuki H, Tominaga T, Dirix LY, Gion M: Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am 1999;5: 101-111.
23. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F, Milano G: Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995;13:1663-1670.
24. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322-1327.
25. Nishimura G, Terada I, Kobayashi T, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Kayahara M, Shimizu K, Ohta T, Miwa K: Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep 2002;9:479-482.
26. Morita T, Matsuzaki A, Suzuki K, Tokue A: Role of thymidine phosphorylase in biomodulation of fluoropyrimidines. Curr Pharm Biotechnol 2001;2:257-267.
27. Suzuki K, Morita T, Hashimoto S, Tokue A: Thymidine phosphorylase/platelet-derived endothelial cell growth factor (PD-ECGF) associated with prognosis in renal cell carcinoma. Urol Res 2001;29:7-12.
28. Imazono Y, Takebayashi Y, Nishiyama K, Akiba S, Miyadera K, Yamada Y, Akiyama S, Ohi Y: Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol 1997;15:2570-2578.
29. Robson CJ, Churchill BM, Anderson W: The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297-301.
30. TNM Classification of Malignant Tumours, ed 3. Geneva, International Union against Cancer, 1978.
31. Nishida M, Hino A, Mori K, Matsumoto T, Yoshikubo T, Ishitsuka H: Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 1996;19:1407-1411.
32. Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, Nagasue N, Yamana H, Hirakawa YS, Chung K, Ikeda T, Takasaki K, Oka M, Kameyama M, Toi M, Fujii H, Kitamura M, Murai M, Sasaki H, Ozono S, Makuuchi H, Shimada Y, Onishi Y, Aoyagi S, Mizutani K, Ogawa M, Nakao A, Kinoshita H, Tono T, Imamoto H, Nakashima Y, Manabe T: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 2000;17:33-38.
33. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Takechi T, Okabe H, Fukushima M, Kitajima M: Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. Anticancer Res 1999;19:5635-5640.
34. Nagakawa T, Kayahara M, Ohta T, Kitagawa H, Mikami K, Kurata T, Otsuji S: Dihydropyrimidine dehydrogenase activity in human pancreatic tumor tissues. Cancer Invest 2000;18:516-520.
35. Jiang W, Lu Z, He Y, Diasio RB: Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: Implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 1997;3:395-399.
36. Fujiwaki R, Hata K, Nakayama K, Fukumoto M, Miyazaki K: Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer. J Clin Oncol 2000;18:3946-3951.
37. Morita T, Matsuzaki A, Tokue A: Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA. Int J Cancer 2001;92:451-456.
38. Morita T, Tokue A: Biomodulation of 5-fluorouracil by interferon α in human renal carcinoma cells: Relation to the expression of thymidine phosphorylase. Cancer Chem Pharm 1999;44:91-96.
39. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998;58:685-690.
40. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Kitajima M, Takechi T, Okabe H, Fukushima M: Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 1999;5:883-889.